{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:15:17Z","timestamp":1778512517779,"version":"3.51.4"},"posted":{"date-parts":[[2026,4,14]]},"group-title":"In Review","reference-count":71,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,4,6]]},"abstract":"<title>Abstract<\/title>\n                <p>Long-acting (LA) antiretroviral agents offer a promising strategy to overcome adherence challenges in HIV prevention and treatment. However, their efficacy in early life has not been evaluated. Using a highly translational newborn macaque model of simian immunodeficiency virus (SIV) infection, we assessed the preventive and therapeutic potential of LA lenacapavir (LEN), alone or in combination with cabotegravir (CAB). Despite its efficacy in adult pre-exposure prophylaxis setting, early LEN monotherapy failed to prevent viral acquisition following intravenous SIV exposure at birth and resulted in virologic failure in infected infants. In contrast, combined administration of LA LEN and LA CAB rapidly suppressed viremia within 2 weeks and maintained undetectable viral loads for up to 1 month. Initiation of combination therapy at 2 days post infection led to rapid virus control and sustained virologic remission in majority of infants following analytical treatment interruption. By comparison, CAB-based regimens incorporating subtherapeutic doses of either LEN or rilpivirine (RPV) were ineffective in preventing infection. Together, these findings demonstrate that LA LEN monotherapy is insufficient for prevention or treatment following early-life HIV exposure and highlight the importance of early initiation of potent LA combination regimens to overcome adherence barriers and achieve potential pediatric HIV remission.<\/p>","DOI":"10.21203\/rs.3.rs-9336128\/v1","type":"posted-content","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:10:52Z","timestamp":1776179452000},"source":"Crossref","is-referenced-by-count":0,"title":["Initiation of Long-Acting Antiretroviral Combinations Achieve Sustained Virologic Remission in Early-Life SIV Infection"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1742-0979","authenticated-orcid":false,"given":"Huanbin","family":"Xu","sequence":"first","affiliation":[{"name":"Tulane University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4081-8985","authenticated-orcid":false,"given":"Xiaolei","family":"Wang","sequence":"additional","affiliation":[{"name":"Tulane National Primate Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LI","family":"MA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice","family":"Vincent","sequence":"additional","affiliation":[{"name":"Tulane University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Zhong","family":"Liu","sequence":"additional","affiliation":[{"name":"Tulane University School of Public Health and Tropical Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0212-9548","authenticated-orcid":false,"given":"Lara","family":"Doyle-Meyers","sequence":"additional","affiliation":[{"name":"Tulane National Primate Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3744-496X","authenticated-orcid":false,"given":"Lori","family":"Rowe","sequence":"additional","affiliation":[{"name":"Tulane National Primate Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eddie","family":"Xu","sequence":"additional","affiliation":[{"name":"Tulane  University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Krzykwa","sequence":"additional","affiliation":[{"name":"Tulane University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6298-2391","authenticated-orcid":false,"given":"Ronald","family":"Veazey","sequence":"additional","affiliation":[{"name":"Tulane National Primate Research Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mackenzie","family":"Cottrell","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-4621","authenticated-orcid":false,"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Rutgers, the State University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/COH.0000000000000740","article-title":"Role of islatravir in HIV treatment and prevention: an update","volume":"17","author":"Derbalah A","year":"2022","unstructured":"Derbalah A, Karpick HC, Maize H, Skersick P, Cottrell M, Rao GG (2022) Role of islatravir in HIV treatment and prevention: an update. Curr Opin HIV AIDS 17:240\u2013246","journal-title":"Curr Opin HIV AIDS"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/phar.2922","article-title":"Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists","volume":"44","author":"Sherman EM","year":"2024","unstructured":"Sherman EM et al (2024) Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists. Pharmacotherapy 44:494\u2013538","journal-title":"Pharmacotherapy"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40121-017-0184-8","article-title":"Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study","volume":"7","author":"Osiyemi O","year":"2018","unstructured":"Osiyemi O et al (2018) Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study. Infect Dis Ther 7:147\u2013159Pharmacokinetics","journal-title":"Infect Dis Ther"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women","volume":"385","author":"Landovitz RJ","year":"2021","unstructured":"Landovitz RJ et al (2021) Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med 385:595\u2013608","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection","volume":"386","author":"Segal-Maurer S","year":"2022","unstructured":"Segal-Maurer S et al (2022) Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med 386:1793\u20131803","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe S","year":"2022","unstructured":"Delany-Moretlwe S et al (2022) Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet 399:1779\u20131789","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-Yearly Lenacapavir or Daily F\/TAF for HIV Prevention in Cisgender Women","volume":"391","author":"Bekker LG","year":"2024","unstructured":"Bekker LG et al (2024) Twice-Yearly Lenacapavir or Daily F\/TAF for HIV Prevention in Cisgender Women. N Engl J Med 391:1179\u20131192","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S2352-3018(24)00310-2","article-title":"Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084\u2009\u2013\u200901): a single-arm, open-label, phase 2b trial","volume":"12","author":"Stranix-Chibanda L","year":"2025","unstructured":"Stranix-Chibanda L et al (2025) Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084\u2009\u2013\u200901): a single-arm, open-label, phase 2b trial. Lancet HIV 12:e252\u2013e260","journal-title":"Lancet HIV"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","article-title":"Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons","volume":"392","author":"Kelley CF","year":"2025","unstructured":"Kelley CF et al (2025) Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med 392:1261\u20131276","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1126\/science.1248707","article-title":"Long-acting integrase inhibitor protects macaques from intrarectal simian\/human immunodeficiency virus","volume":"343","author":"Andrews CD","year":"2014","unstructured":"Andrews CD et al (2014) Long-acting integrase inhibitor protects macaques from intrarectal simian\/human immunodeficiency virus. Science 343:1151\u20131154","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"270ra274","DOI":"10.1126\/scitranslmed.3010298","article-title":"A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge","volume":"7","author":"Andrews CD","year":"2015","unstructured":"Andrews CD et al (2015) A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med 7:270ra274","journal-title":"Sci Transl Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"270ra275","DOI":"10.1126\/scitranslmed.3010297","article-title":"The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge","volume":"7","author":"Radzio J","year":"2015","unstructured":"Radzio J et al (2015) The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci Transl Med 7:270ra275","journal-title":"Sci Transl Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"7762","DOI":"10.1128\/AAC.01937-15","article-title":"Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase","volume":"59","author":"Melody K","year":"2015","unstructured":"Melody K, McBeth S, Kline C, Kashuba AD, Mellors JW, Ambrose Z (2015) Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase. Antimicrob Agents Chemother 59:7762\u20137770","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","author":"Andrews CD","year":"2017","unstructured":"Andrews CD et al (2017) Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. AIDS 31, 461\u2013467"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/infdis\/jiaa095","article-title":"Long-Acting Cabotegravir Protects Macaques Against Repeated Penile Simian-Human Immunodeficiency Virus Exposures","volume":"222","author":"Dobard C","year":"2020","unstructured":"Dobard C et al (2020) Long-Acting Cabotegravir Protects Macaques Against Repeated Penile Simian-Human Immunodeficiency Virus Exposures. J Infect Dis 222:391\u2013395","journal-title":"J Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/COH.0000000000000599","article-title":"Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1","volume":"15","author":"Markowitz M","year":"2020","unstructured":"Markowitz M, Grobler JA (2020) Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1. Curr Opin HIV AIDS 15:27\u201332","journal-title":"Curr Opin HIV AIDS"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41586-021-04279-4","article-title":"Long-acting capsid inhibitor protects macaques from repeat SHIV challenges","volume":"601","author":"Vidal SJ","year":"2022","unstructured":"Vidal SJ et al (2022) Long-acting capsid inhibitor protects macaques from repeat SHIV challenges. Nature 601:612\u2013616","journal-title":"Nature"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"104764","DOI":"10.1016\/j.ebiom.2023.104764","article-title":"Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV","volume":"95","author":"Swanstrom AE","year":"2023","unstructured":"Swanstrom AE et al (2023) Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV. EBioMedicine 95:104764","journal-title":"EBioMedicine"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167818","article-title":"Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model","volume":"133","author":"Bekerman E","year":"2023","unstructured":"Bekerman E et al (2023) Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model. J Clin Invest 133","journal-title":"J Clin Invest"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S2352-3018(20)30106-5","article-title":"Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial","volume":"7","author":"Landovitz RJ","year":"2020","unstructured":"Landovitz RJ et al (2020) Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV 7:e472\u2013e481","journal-title":"Lancet HIV"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link JO","year":"2020","unstructured":"Link JO et al (2020) Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature 584:614\u2013618","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1016\/S2352-3018(21)00184-3","article-title":"Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study","volume":"8","author":"Orkin C","year":"2021","unstructured":"Orkin C et al (2021) Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Lancet HIV 8:e668\u2013e678","journal-title":"Lancet HIV"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"ofab439","DOI":"10.1093\/ofid\/ofab439","article-title":"Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study","volume":"8","author":"Smith GHR","year":"2021","unstructured":"Smith GHR et al (2021) Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study. Open Forum Infect Dis 8:ofab439","journal-title":"Open Forum Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton ET","year":"2021","unstructured":"Overton ET et al (2021) Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet 396:1994\u20132005","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","article-title":"Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment","volume":"36","author":"Swindells S","year":"2022","unstructured":"Swindells S et al (2022) Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. AIDS 36:185\u2013194","journal-title":"AIDS"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial","volume":"10","author":"Ramgopal MN","year":"2023","unstructured":"Ramgopal MN et al (2023) Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV 10:e566\u2013e577","journal-title":"Lancet HIV"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study","volume":"76","author":"Overton ET","year":"2023","unstructured":"Overton ET et al (2023) Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study. Clin Infect Dis 76:1646\u20131654","journal-title":"Clin Infect Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"ofae125","DOI":"10.1093\/ofid\/ofae125","article-title":"Case Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial","volume":"11","author":"Gandhi M","year":"2024","unstructured":"Gandhi M et al (2024) Case Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial. Open Forum Infect Dis 11:ofae125","journal-title":"Open Forum Infect Dis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/jac\/dkae308","article-title":"Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror Phase 3 results","volume":"79","author":"Serris A","year":"2024","unstructured":"Serris A et al (2024) Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror Phase 3 results. J Antimicrob Chemother 79:2932\u20132938","journal-title":"J Antimicrob Chemother"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"10550","DOI":"10.1038\/s41467-024-54783-0","article-title":"SHIV remission in macaques with early treatment initiation and ultra long-lasting antiviral activity","volume":"15","author":"Daly MB","year":"2024","unstructured":"Daly MB et al (2024) SHIV remission in macaques with early treatment initiation and ultra long-lasting antiviral activity. Nat Commun 15:10550","journal-title":"Nat Commun"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"ofaf651","DOI":"10.1093\/ofid\/ofaf651","article-title":"Lenacapavir Plus Cabotegravir as Combination Treatment: Real-world Use Cases From the National Clinician Consultation Center","volume":"12","author":"Saberi P","year":"2025","unstructured":"Saberi P, McAnaney C, Nakayoshi A, Bositis C, Gandhi M, Chu C (2025) Lenacapavir Plus Cabotegravir as Combination Treatment: Real-world Use Cases From the National Clinician Consultation Center. Open Forum Infect Dis 12:ofaf651","journal-title":"Open Forum Infect Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/cid\/ciae500","article-title":"Viral Suppression Rates at 48 Weeks in People With HIV Starting Long-Acting Cabotegravir\/Rilpivirine With Initial Viremia","volume":"80","author":"Hickey MD","year":"2025","unstructured":"Hickey MD et al (2025) Viral Suppression Rates at 48 Weeks in People With HIV Starting Long-Acting Cabotegravir\/Rilpivirine With Initial Viremia. Clin Infect Dis 80:864\u2013870","journal-title":"Clin Infect Dis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"106067","DOI":"10.1016\/j.ebiom.2025.106067","article-title":"Preclinical evaluation of long-acting cabotegravir and rilpivirine for HIV post-exposure prophylaxis in a macaque model","volume":"123","author":"Srinivasan P","year":"2026","unstructured":"Srinivasan P et al (2026) Preclinical evaluation of long-acting cabotegravir and rilpivirine for HIV post-exposure prophylaxis in a macaque model. EBioMedicine 123:106067","journal-title":"EBioMedicine"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1038\/s41467-022-32554-z","article-title":"Early treatment regimens achieve sustained virologic remission in infant macaques infected with SIV at birth","volume":"13","author":"Wang X","year":"2022","unstructured":"Wang X et al (2022) Early treatment regimens achieve sustained virologic remission in infant macaques infected with SIV at birth. Nat Commun 13:4823","journal-title":"Nat Commun"},{"key":"ref35","author":"Ma L","year":"2025","unstructured":"Ma L et al (2025) Impact of Delayed Early Antiretroviral Therapy Initiation on Treatment Outcomes in Infant Macaques Exposed to SHIVAD8. Viruses 17"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1126\/science.abb4808","article-title":"Structural and mechanistic bases for a potent HIV-1 capsid inhibitor","volume":"370","author":"Bester SM","year":"2020","unstructured":"Bester SM et al (2020) Structural and mechanistic bases for a potent HIV-1 capsid inhibitor. Science 370:360\u2013364","journal-title":"Science"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"eaea0947","DOI":"10.1126\/scitranslmed.aea0947","article-title":"Lenacapavir treatment-emergent HIV-1 capsid resistance mutations are frequently associated with replication defects","volume":"18","author":"Pennetzdorfer N","year":"2026","unstructured":"Pennetzdorfer N et al (2026) Lenacapavir treatment-emergent HIV-1 capsid resistance mutations are frequently associated with replication defects. Sci Transl Med 18:eaea0947","journal-title":"Sci Transl Med"},{"key":"ref38","author":"Discovery C","year":"2024","unstructured":"Discovery C et al (2024) Chai-1: Decoding the molecular interactions of life. bioRxiv, 2024.2010.2010.615955"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1038\/s41564-022-01247-0","article-title":"Evasion of cGAS and TRIM5 defines pandemic HIV","volume":"7","author":"Zuliani-Alvarez L","year":"2022","unstructured":"Zuliani-Alvarez L et al (2022) Evasion of cGAS and TRIM5 defines pandemic HIV. Nat Microbiol 7:1762\u20131776","journal-title":"Nat Microbiol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41591-019-0560-x","article-title":"A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model","volume":"25","author":"Yant SR","year":"2019","unstructured":"Yant SR et al (2019) A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model. Nat Med 25:1377\u20131384","journal-title":"Nat Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1310\/hct1405-192","article-title":"Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor","volume":"14","author":"Spreen W","year":"2013","unstructured":"Spreen W et al (2013) Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials 14:192\u2013203","journal-title":"HIV Clin Trials"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/S2352-3018(23)00113-3","article-title":"Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2\/3 trial","volume":"10","author":"Ogbuagu O","year":"2023","unstructured":"Ogbuagu O et al (2023) Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2\/3 trial. Lancet HIV 10:e497\u2013e505","journal-title":"Lancet HIV"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3018(22)00291-0","article-title":"Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial","volume":"10","author":"Gupta SK","year":"2023","unstructured":"Gupta SK et al (2023) Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Lancet HIV 10:e15\u2013e23","journal-title":"Lancet HIV"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/hiv.13370","article-title":"Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy","volume":"24","author":"D'Amico R","year":"2023","unstructured":"D'Amico R et al (2023) Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy. HIV Med 24:202\u2013211","journal-title":"HIV Med"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/cid\/ciad511","article-title":"Long-acting Injectable Cabotegravir\/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy","volume":"78","author":"Brock JB","year":"2024","unstructured":"Brock JB, Herrington P, Hickman M, Hickman A (2024) Long-acting Injectable Cabotegravir\/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy. Clin Infect Dis 78:122\u2013124","journal-title":"Clin Infect Dis"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/hiv.13679","article-title":"Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net)","volume":"25","author":"Ring K","year":"2024","unstructured":"Ring K et al (2024) Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net). HIV Med 25:1125\u20131134","journal-title":"HIV Med"},{"key":"ref47","author":"Conti GN","year":"2025","unstructured":"Conti GN et al (2025) Efficacy and Safety of Cabotegravir-Rilpivirine in PLWH: A Real-World Study. Viruses 17"},{"key":"ref48","author":"Bekker LG","year":"2020","unstructured":"Bekker LG et al (2020) Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women. EClinicalMedicine 21, 100303"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrmicro3503","article-title":"HIV-1 capsid: the multifaceted key player in HIV-1 infection","volume":"13","author":"Campbell EM","year":"2015","unstructured":"Campbell EM, Hope TJ (2015) HIV-1 capsid: the multifaceted key player in HIV-1 infection. Nat Rev Microbiol 13:471\u2013483","journal-title":"Nat Rev Microbiol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e1010109","DOI":"10.1371\/journal.ppat.1010109","article-title":"HIV-1 capsid is the key orchestrator of early viral replication","volume":"17","author":"Zila V","year":"2021","unstructured":"Zila V, Muller TG, Muller B, Krausslich HG (2021) HIV-1 capsid is the key orchestrator of early viral replication. PLoS Pathog 17:e1010109","journal-title":"PLoS Pathog"},{"key":"ref51","article-title":"Structure, Function, and Interactions of the HIV-1 Capsid Protein","volume":"11","author":"Rossi E","year":"2021","unstructured":"Rossi E, Meuser ME, Cunanan CJ, Cocklin S (2021) Structure, Function, and Interactions of the HIV-1 Capsid Protein. Life (Basel) 11","journal-title":"Life (Basel)"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"e2220545120","DOI":"10.1073\/pnas.2220545120","article-title":"Structural insights into HIV-1 polyanion-dependent capsid lattice formation revealed by single particle cryo-EM","volume":"120","author":"Highland CM","year":"2023","unstructured":"Highland CM, Tan A, Ricana CL, Briggs JAG, Dick RA (2023) Structural insights into HIV-1 polyanion-dependent capsid lattice formation revealed by single particle cryo-EM. Proc Natl Acad Sci U S A 120:e2220545120","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"21072","DOI":"10.1021\/acs.jmedchem.5c01625","article-title":"Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV-1 Treatment and Pre-exposure Prophylaxis","volume":"68","author":"Canales E","year":"2025","unstructured":"Canales E et al (2025) Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV-1 Treatment and Pre-exposure Prophylaxis. J Med Chem 68:21072\u201321094","journal-title":"J Med Chem"},{"key":"ref54","author":"Bester SM","year":"2022","unstructured":"Bester SM et al (2022) Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir. mBio 13, e0180422"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jac\/dkac388","article-title":"Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals","volume":"78","author":"Nka AD","year":"2022","unstructured":"Nka AD et al (2022) Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals. J Antimicrob Chemother 78:272\u2013275","journal-title":"J Antimicrob Chemother"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1089\/aid.2018.0265","article-title":"A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV","volume":"35","author":"Cranston RD","year":"2019","unstructured":"Cranston RD et al (2019) A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. AIDS Res Hum Retroviruses 35:794\u2013804","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(25)00405-2","article-title":"Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study","volume":"405","author":"Jogiraju V","year":"2025","unstructured":"Jogiraju V et al (2025) Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study. Lancet 405:1147\u20131154","journal-title":"Lancet"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/jac\/dkab503","article-title":"Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study","volume":"77","author":"Margot N","year":"2022","unstructured":"Margot N et al (2022) Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study. J Antimicrob Chemother 77:989\u2013995","journal-title":"J Antimicrob Chemother"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/ajhp\/zxad223","article-title":"A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV","volume":"80","author":"Prather C","year":"2023","unstructured":"Prather C, Lee A, Yen C, Lenacapavir (2023) A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV. Am J Health Syst Pharm 80:1774\u20131780","journal-title":"Am J Health Syst Pharm"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"117125","DOI":"10.1016\/j.bcp.2025.117125","article-title":"Lenacapavir: A capsid inhibitor for HIV-1 treatment and prevention","volume":"240","author":"Clercq E","year":"2025","unstructured":"De Clercq E et al (2025) Lenacapavir: A capsid inhibitor for HIV-1 treatment and prevention. Biochem Pharmacol 240:117125","journal-title":"Biochem Pharmacol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"a006890","DOI":"10.1101\/cshperspect.a006890","article-title":"HIV DNA integration","volume":"2","author":"Craigie R","year":"2012","unstructured":"Craigie R, Bushman FD (2012) HIV DNA integration. Cold Spring Harb Perspect Med 2:a006890","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"Suppl 4","key":"ref62","first-page":"83","article-title":"Ontogeny and drug metabolism in newborns","volume":"25","author":"Dotta A","year":"2012","unstructured":"Dotta A, Chukhlantseva N (2012) Ontogeny and drug metabolism in newborns. J Matern Fetal Neonatal Med 25(Suppl 4):83\u201384","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"Suppl 2","key":"ref63","doi-asserted-by":"crossref","first-page":"SP307","DOI":"10.2131\/jts.34.SP307","article-title":"Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children","volume":"34","author":"Yokoi T","year":"2009","unstructured":"Yokoi T (2009) Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children. J Toxicol Sci 34(Suppl 2):SP307\u2013312","journal-title":"J Toxicol Sci"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1177541","DOI":"10.3389\/fphar.2023.1177541","article-title":"Ontogeny of CYP3A and UGT activity in preterm piglets: a translational model for drug metabolism in preterm newborns","volume":"14","author":"Buyssens L","year":"2023","unstructured":"Buyssens L et al (2023) Ontogeny of CYP3A and UGT activity in preterm piglets: a translational model for drug metabolism in preterm newborns. Front Pharmacol 14:1177541","journal-title":"Front Pharmacol"},{"key":"ref65","first-page":"1499","volume":"82","author":"Paik J","year":"2022","unstructured":"Paik J, Lenacapavir (2022) First Approval Drugs 82:1499\u20131504","journal-title":"First Approval Drugs"},{"key":"ref66","first-page":"495","article-title":"Pharmacological outlook of Lenacapavir: a novel first-in-class Long-Acting HIV-1 Capsid Inhibitor","volume":"31","author":"Perri G","year":"2023","unstructured":"Di Perri G (2023) Pharmacological outlook of Lenacapavir: a novel first-in-class Long-Acting HIV-1 Capsid Inhibitor. Infez Med 31:495\u2013499","journal-title":"Infez Med"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/COH.0000000000000713","article-title":"Lenacapavir: a first-in-class HIV-1 capsid inhibitor","volume":"17","author":"Dvory-Sobol H","year":"2022","unstructured":"Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS (2022) Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr Opin HIV AIDS 17:15\u201321","journal-title":"Curr Opin HIV AIDS"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1021\/acs.molpharmaceut.3c00626","article-title":"A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent","volume":"20","author":"Subramanian R","year":"2023","unstructured":"Subramanian R et al (2023) A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent. Mol Pharm 20:6213\u20136225Lenacapavir","journal-title":"Mol Pharm"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"23259582251390622","DOI":"10.1177\/23259582251390622","article-title":"Twice-Yearly Injectable Pre-Exposure Prophylaxis With Lenacapavir: Redefining Adherence and Access in the Global Fight Against HIV","volume":"24","author":"Sah S","year":"2025","unstructured":"Sah S, Iqbal U, Mishra T, Ullah N, Yadav T (2025) Twice-Yearly Injectable Pre-Exposure Prophylaxis With Lenacapavir: Redefining Adherence and Access in the Global Fight Against HIV. J Int Assoc Provid AIDS Care 24:23259582251390622","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.chom.2023.01.016","article-title":"Antiretroviral therapy reveals triphasic decay of intact SIV genomes and persistence of ancestral variants","volume":"31","author":"Fray EJ","year":"2023","unstructured":"Fray EJ et al (2023) Antiretroviral therapy reveals triphasic decay of intact SIV genomes and persistence of ancestral variants. Cell Host Microbe 31:356\u2013372e355","journal-title":"Cell Host Microbe"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijpharm.2018.10.017","article-title":"Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles","volume":"552","author":"Krovi SA","year":"2018","unstructured":"Krovi SA et al (2018) Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles. Int J Pharm 552:371\u2013377","journal-title":"Int J Pharm"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9336128\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9336128\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:01:25Z","timestamp":1778511685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9336128\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":71,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9336128\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,4,14]]},"subtype":"preprint"}}